Physicians specializing in hematopoietic SCT (HSCT) occasionally encounter the difficult situation of deciding whether to proceed with an allogeneic HSCT for a high-risk hematologic malignancy in a patient who has a different concomitant incurable but treatable low-grade neoplasm. In such patients, the risk of the low-grade neoplasm demonstrating altered natural history and progressing more quickly to become life threatening in the setting of immunosuppression is theoretically increased, but the magnitude of this risk is unknown. With the increasing availability of targeted therapies with relatively favorable safety profiles prolonging survival in these patients, the unique possibility of entering into an allogeneic HSCT for a high-risk hematologic malignancy while planning post-transplant targeted therapy for the low-grade neoplasm emerges. However, the likelihood that a patient will be a suitable candidate for such effective, otherwise relatively non-toxic targeted therapy after what can be a very complicated course post transplant is impossible to determine a priori.
We have recently encountered this situation with a previously healthy 38-year-old man who presented with fatigue, easy bruising and nausea. Complete blood count revealed a hemoglobin of 8.3 g/dL, platelet count of 22 000 Â 10 9 /L and a leukocyte count of 157 000 Â 10 9 /L with 77% circulating blasts. A diagnosis of pre-B-cell ALL was made based on BM biopsy demonstrating near 100% cellularity with 490% blasts, expressing CD19, cytoplasmic CD22, nuclear TdT (dim), CD15, CD34 and HLA-DR. Cytogenetics revealed 14 out of 20 metaphases with a translocation (4;11)(q21;q23), and 9 of these had an additional X chromosome. Fluorescence in-situ hybridization studies on the BM specimen confirmed that 94.2% of nuclei had AF4/MLL fusion.
He developed coffee-ground emesis and melena prior to beginning induction chemotherapy. Upper endoscopy demonstrated external compression of the lesser curvature of the stomach, and a subsequent computed tomography scan demonstrated a 9.2-cm mass extending from the inferior portion of the gastric antrum along with multiple complex cystic liver lesions. Biopsy of the primary tumor or metastatic lesions was not undertaken at that time because of his tenuous clinical situation, including profound thrombocytopenia and ongoing disseminated intravascular coagulation. He commenced induction chemotherapy with hyper-CVAD, and after two cycles, he achieved a complete morphological and molecular remission.
He then proceeded to subtotal gastrectomy and an excisional biopsy of a liver mass from segments 3 to 6. Pathology showed mixed epithelioid and spindle cell gastrointestinal stromal tumor (GIST) with extensive fibrosis and necrosis forming a 7.3-cm mass. Molecular testing by PCR and sequencing revealed no mutations within KIT exon 9, KIT exon 11, PDGFRA exon 12 and PDGFRA exon 18. The surgical margins were free of tumor, and the liver lesions were consistent with metastatic GIST. He received a third cycle of hyper-CVAD, and initiated imatinib mesylate 400 mg by mouth daily for his metastatic GIST. He continued imatinib mesylate for approximately 1 month pre transplant, and had repeat baseline imaging studies prior to transplant (Figure 1a) .
He subsequently underwent myeloablative conditioning using CY and TBI of 1320 cGy followed by allogeneic HSCT. The plan was to start post-transplant imatinib mesylate for metastatic GIST upon sustained hematopoietic engraftment. He tolerated the conditioning well, but he had prolonged, transfusion-requiring anemia and thrombocytopenia post transplant likely as a consequence of multiple complications including acute GVHD involving the skin and gastrointestinal tract (overall grade 3), hypogammaglobulinemia, calcineurin inhibitor-associated thrombotic microangiopathy, polymicrobial pneumonia (adenovirus, Aspergillus versicolor, Pseudomonas aeruginosa, and viridans group Streptococcus) and Clostridium difficile colitis. These complications resulted in the requirement for prolonged immunosuppression with corticosteroids and mycophenolate mofetil, supplemental immune globulin a b Figure 1 . Contrast enhanced (portal phase) computed tomography coronal section of the abdomen demonstrating hepatic metastases (a) at pre-transplant evaluation and (b) at 6 months post-HSCT.
and i.v. antimicrobials including dual antifungal coverage with liposomal amphotericin and posaconazole. As a result of his complex course, particularly cytopenias, it was not possible to reintroduce imatinib mesylate immediately post transplant. Despite this, many of his metastatic hepatic lesions remained stable or even regressed in size, (Figure 1b) demonstrating partial response of the metastatic GIST after allogeneic HSCT. It is not possible to determine precisely whether the GIST lesions regressed in size as a result of conditioning chemotherapy or during his period of GVHD, because his first GIST restaging did not occur until his day þ 100 evaluation, and he had developed grade 3 acute GVHD several weeks prior to this time. By 10 months postallogeneic HSCT, our patient had improvement in his cytopenias that allowed reintroduction of attenuated doses of imatinib, and by 1 year post-allogeneic HSCT, he has been able to resume imatinib at 400 mg by mouth daily.
Our patient had high-risk ALL on the basis of molecular and clinical features including translocation (4;11), and without allogeneic transplantation in first remission, expected median survival in similar patients would be o2 years 1 . His other malignancy, GIST metastatic to liver, is currently associated with a much more favorable prognosis with a 4-year OS of 480% in the era of imatinib mesylate 2 . However, prior to the advent of imatinib, median progression free and OS for metastatic GIST patients would have been much poorer---approximately 7 months and 17 months, respectively 3 . Considering his molecular and clinicopathologic phenotype, his metastatic GIST tumor did not have favorable features 4, 5 . Despite our inability to resume effective targeted tyrosine kinase inhibitor therapy during a timeframe in which over half of non-immunosuppressed patients would be expected to progress, the metastatic GIST has not progressed and even demonstrated some area improvement. It is not entirely clear whether his apparent improvement was due to a component of his high-dose conditioning regimen or the possibility of a graft-vs-GIST effect. Nonetheless, this patient's course demonstrates that allogeneic HSCT for high-risk hematologic malignancies can be cautiously considered and applied in the setting of coexistent unrelated, indolent neoplasms.
